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Abstract. Background/Aim: Natural killer (NK) cells are
one of the lymphocytes clinically used for various cancer
types. Cytotoxicity of NK cells to cholangiocarcinoma (CC),
however, has not yet been studied. Nor NK cell therapy
against CC has been clinically applied. In this study,
relevance of NK cell therapy for anti-tumor efficacy against
CC was pre-clinically investigated. Materials and Methods:
Human HuCCT-1 cells, an intrahepatic CC cell line, were
xenografted into nude mice. The HuCCT-1 tumor-bearing
nude mice then received multiple infusions of ex vivo-
expanded human NK cells (SMT01) and in vivo cytotoxic
activity of the NK cells against the CC cells was evaluated.
Results: SMT01 infusion resulted in significant inhibition of
the CC tumor growth. Body weight of the mice administrated
with chemotherapy was found to be maintained at the lowest
level among all treatment groups while all the SMT01
infusion groups well maintained their body weight.
Conclusion: The present in vivo study demonstrates that NK
cells contain cytolytic activity against cholangiocarcinoma
and show beneficial effect of NK cell therapy in relevance to
quality of life. Further investigation of the NK cell-based
immunotherapy can be useful to determine cancer
therapeutics for the specific tumor.
Cholangiocarcinoma (CC) is a type of cancer that arises from
the epithelium of bile duct. CC is a relatively rare cancer with
an annual incidence of <6 cases per 100,000 persons
worldwide, but the incidence number keeps increasing,
especially in certain Asian countries including China, South
Korea, and Thailand (1-3). CC is classified as an invasive
adenocarcinoma which is considered to be incurable, when
diagnosed at an advance stage. The 5-year survival rate for
people with early-stage extrahepatic and intrahepatic CC is 30%
and 15%, respectively. However, most patients are found to be
inoperable at advanced stages of the disease at the time of
diagnosis which results in 2-5% 5-year survival rate. While no
potentially curative treatment for CC exists, gemcitabine/cis-
diammineplatinum (II) dichloride (Gem/CDDP) regimen is
widely administered to patients at an inoperable stage. 
Natural killer (NK) cells are one of the lymphocytes with
natural cytotoxicity, recognizing and lysing malignant and
virally infected cells without prior sensitization (4, 5). These
cells are now widely used as an innovative immune-therapy
against various types of cancers lacking major
histocompatibility complex (MHC) class I, while normal cells
expressing MHC I molecules are recognized by the NK cell’s
receptor, killer cell immunoglobulin-like receptor (KIR),
inhibiting the NK cell’s cytotoxicity (6, 7). The NK activating
signaling is conferred by NKG2D (natural-killer group 2D),
a lectin-like activating receptor (8, 9). When MHC I
expression is lost or down-regulated in cancer cells, the NK
inhibitory signal is abrogated and NK cells are activated to
kill the malignant target cancer cells. Identification of NK
cells can be done by detecting CD56 or CD16 expression and
the absence of CD3 expression (10, 11). The CD56
expressing NK cells can be further divided into two subsets,
CD56bright and CD56dim NK cell population (12). 
Clinical use of NK cells against various cancers has
already been performed. The first trials in humans focused
on the use of autologous NK cells. The efficacy, however,
was limited due to autologous NK cell inhibition by self-
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MHC. As the NK cell receptors were further characterized,
the next clinical approach using NK cells focused on
allogeneic NK cells obtained from healthy haploidentical
donors. This approach has allowed NK cells to avoid tumor-
induced suppression and demonstrated greater tumor-killing
activity (13, 14). Indeed, the strategy of administrating
allogeneic NK cells to cancer patients has adoptively been
used (15).  
No immune cell therapy including NK cells for CC has
been yet developed. There are no research reports on the
usage of the NK cells for the treatment CC. The primary goal
of this study was to investigate whether NK cell therapy has
any clinical anti-tumor efficacy against CC. To this direction,
we examined whether NK cells are cytotoxic to CC cells and
can be used as cancer therapeutics. 
Materials and Methods
Study design of the in vivo study in Nude mice. NCr athymic nude
mice (BALB/cSlc-nu/nu) (Charles River Laboratories, Atsugi, Japan
SLC, Inc) were handled and housed in microisolator cages
following OECD Good Laboratory Practice regulations
(ENV/MC/CHEM(98)17 as revised in 1997) and Good Laboratory
Practice for Nonclinical Laboratory Studies (21CFR Part 58, Food
and Drug Administration, United States of America (Apr. 1, 2015).
To evaluate dosage dependent safety and toxicity, three different
doses of SMT01 (NK cells) were determined (Figure 1A): Low dose
infusion of 4×104 cells/animal which corresponds to 2×106 cells/kg
in human. Intermediate and high doses of 2×105 cells/animal and
1×106 cells/animal, respectively. The ex vivo expanded NK cells
were then intravenously injected (tail vein injection at 2 ml/min
using 26 G syringe, 0.2 ml/animal) to 50 male and female mice
(weight range 18.7~22.5 g and 16.1~18.8 g, respectively, at 6
weeks) at 2 times per 3 weeks for 27 weeks. A total of 18 SMT01
infusions were performed. The same nude mice were used for the
dosage efficacy study (Figure 1B). To do this, transplantation and
engraftment was firstly done by subcutaneous injection of HuCCT-
1 cells (5×106 cells/0.2 ml) into 10 nude mice per group (G1-G5):
G1, normal saline (negative control); G2-G4, SMT01 infusions; G5,
Gem+CDDP (positive control). Eight well engrafted nude mice with
a 84~119 mm3 tumor volume (19.3~20.5 g body weight range) from
each group were then selected and treated. 
The nude mice bearing a HuCCT-1 tumor were administered
intravenously with SMT01 5 times with 10 days of interval. Chemo-
administration as a positive control group was also done with
Gemcitabine (Gem) and Cis-diammineplatinum (II) dichloride
(CDDP) at 120 mg/kg and 3 mg/kg, respectively. SMT01 infusion
was performed to three different mice groups (Table I): SMT01
infusions, G2-G4: G2, low dose (4×104 cell/animal); G3,
intermediate dose (2×105 cells/animal); G4, high dose (1×106
cells/animal). G1 and G5, negative control (normal Saline) and
positive control (CDDP+Gem), respectively. Cell injection was done
by using a disposable syringe (26G, 1 ml). Injection volume was
0.2 ml/animal. At 14 days after the final infusion, the tumor-bearing
mice were sacrificed and processed for evaluation (Figure 1B). 
Preparation and ex vivo expansion of NK cells. Blood was obtained
alternatively from two healthy donors and used for peripheral blood
mononuclear cell (PBMC) isolation during the preclinical study.
CD3+ T cell depletion was done by using MACSxpress (Milteyi
Biotec., Seoul, Korea). The T cell depleted PBMC was washed two
times with DPBS buffer and cultured in a T75 flask containing 20
ml of an NK expansion medium (ALyS505NK-IL2 1,000 IU/ml,
Cell Science & Technology Institute Inc., Sendai, Japan). The IL-2
activated NK cells were fed with fresh medium every three days and
transferred to a T175 flask after 5-7 days of culture. The NK cell
expansion was continued for another 7 to 14 days by adding fresh
medium until a desired cell number was reached. The viability and
number of the expanded NK cells was performed by the trypan blue
counting method with an automatic cell counter. 
Human cell lines. Human biliary tract cancer cell lines used for the
study were: HuCCT-1 (intrahepatic) purchased from the Health
Science Research Resources Bank (Osaka, Japan), and SNU1196
(extrahepatic), SNU308 (extrahepatic), and SNU478 (ampulla of
Vater) obtained from the Korean Cell Line Bank (Seoul, Korea).
The cell lines were cultured in RPMI-1640 medium (GIBCO, Seoul,
Korea) supplemented with 10% fetal bovine serum (GIBCO), 100
U/ml penicillin, and 100 mg/ml streptomycin in humidified
atmosphere containing 5% CO2.
Phenotypic flow cytometric analysis. To analyze cell populations of
SMT01, the cells were stained with PE conjugated anti-human
CD56 and anti-human CD40, and FITC conjugated anti-human CD3
and anti-human CD16 monoclonal antibodies (BD Biosciences,
Seoul, Korea). For staining, SMT01 were washed twice in
phosphate buffer saline (PBS) and re-suspended in FACS staining
buffer (PBS with 0.5% bovine serum albumin). The cells were then
stained with the appropriate antibodies at 4˚C for 30 min. After
washing with PBS buffer three times, the cells were analyzed on a
FACS flowcytometer (Beckton Dickinson AriaIII). Gates were set
around NK cells defined as CD56+/CD3– and CD56+/CD16+ to
determine NK cell population. 
Cytotoxicity assay. Cytolytic NK cell activity was measured by
using Cell Counting Kit-8 (CCK-8) (Dojindo Mol. Tech., Rockville,
MD, USA). K562 cells were included as a positive target cell to
compare cytolytic activity of the NK cell against human
cholangiocarcinoma cell lines. SMT01 effector cells were seeded
into the 96-well plates at a density of 1×104 cell per well and
incubated for 24 h. Cell viability of the target cell lines at three
different effector:target (E:T) cell ratios (1:5, 1:1, and 5:1) was
measured by CCK8 kit following the manufacturer’s instructions.
Absorbance was measured at 450 nm using a microplate reader.
Cytotoxic effect was calculated as follows. Cytotoxicity (%)=100%
- ((ODe+t –ODb) – (ODe – ODb))/(ODt – ODb) × 100% (OD,
absorbance; e, effector; t, target; b, blank). 
Histology, immunohistochemistry (IHC) and TUNEL assay. For
histologic evaluation, HuCCT-1 tumor was dissected out from the
nude mice and embedded into paraffin. Four μm tissue sections
were prepared and stained with hematoxylin and eosin (H&E)
according to standard protocols (16). The same tissue sections were
used for IHC experiments. IHC experiments were carried out as
previously described (17, 18). Antibodies used for IHC experiment
were anti-human CD56 (BD Sciences, Seoul, Korea), natural
cytotoxicity triggering receptor 1 (NCR1, BD Sciences), and anti-
human Caspase 3a antibody (Abcam, Seoul, Korea). The tumor
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section slides were also used to conduct in situ detection of
apoptotic cells by TUNEL staining. The TUNEL assay was done by
using TumorTACS in situ Apoptosis kit (R&D Systems,
Minneapolis, MN, USA). Olympus MVX10 was used for
microscopic observation. Photographs from the slide sections were
obtained by using Olympus BX51.
Statistics evaluation. Body weight, tumor volume, and tumor weight
were evaluated by using SAS (Version 9.3, SAS Institute Inc.,
USA). Values are expressed as mean±SD. Bartlett test was used for
homoscedasticity and Dunnett’s t-test was used for statistical
significance. Statistical significance was determined at p<0.05. 
Results  
SMT01, the cytotoxic NK cells expanded from PBMC. To
produce SMT01, NK cells were isolated from human peripheral
blood by using MACSexpress, depleting CD3-positive T cells.
The isolated NK cells were then cultured for 14 days in the
presence of IL2. To determine SMT01’s cell population, the ex
vivo expanded cells were stained with different antibodies
detecting NK cell-antigens CD56/CD3, T cell-antigen CD3, and
other lymphocyte antigens CD40 to identify DC and B cells.
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Figure 1. Study design for the in vivo study in nude mice. A: Dosage-dependent safety and toxicity. B: Dosage efficacy study. The HuCCT-1
xenografted nude mice were initially planned to receive 6 treatments. Since the G1 group (no treatment group) however showed poor status with a
significant tumor growth, 6th treatment was omitted. 
Table I. Dose escalation study of SMT01.
Group (Number of animal)      Injected cell number (cells/animal)    Injected volume (mL/animal)        Mean proliferation rate of Lymphocyte (%)
                                                                                                                                        
                                                                                                                                                                       T cell (male/female)      B cell (male/female)
G1       Negative control (20)                               0                                                      0.2                                       100/100                           100/100
G2       Low dose (20)                                       4×104                                                  0.2                                      97.5/99.1                        99.8/102.2
G3       Intermediate dose (20)                         2×105                                                  0.2                                     98.8/103.3                      104.2/102.2
G4       High dose (20)                                      1×106                                                  0.2                                      97/104.2                        104.2/97.6
Negative control: normal saline.
CD56/CD16 antibodies were also used to determine the NK
cells subtypes. Based on CD56 and CD3 phenotype, the
majority of the expanded cells represented NK cells while 0.2%
was CD3+ T cell population (Figure 2A). 99.2% of SMT01 cell
population was defined as CD56+/CD3– NK cells. CD56dim and
CD56bright types of NK cells were also detected, revealing that
SMT01 contained mostly CD56dim NK cells. 
Cytolytic activity of SMT01 was also evaluated (Figure
2B). To determine cytotoxicity of NK cells, Cell Counting
Kit-8 (CCK-8) was effectively used to count the number of
viable target cells. K562 cells were included as a positive
control to compare the viability of the human intrahepatic
and extrahepatic cholangiocarcinoma (CC) cell lines. As
expected, SMT01 showed an enhanced cytolytic activity to
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Figure 2. Flow cytometry of the ex vivo expanded SMT01 and cytotoxicity against cholangiocarcinoma cell lines. A: Phenotypic cell population of
SMT01. Anti-CD56/CD16 antibodies were used to determine types of NK cells and anti-CD3 antibody was used to detect T cell population. Anti-
CD40 antibody recognizes DC and B cells. B: Cytolytic evaluation of SMT01 against intrahepatic and extrahepatic CC cell lines: HuCCT-1
(intrahepatic), SNU1196 (extrahepatic), SNU308 (extrahepatic), and SNU478 (ampulla of Vater). K562 cell lines were used as a positive control. 
K562 cells. Among the CC cell lines, SMT01 showed the
highest cytolytic activity to HuCCT1 and SNU308 relatively
to SNU1196 and SNU478 cells. This suggested that NK cells
displayed variable cytolytic effects depending on the various
cancer types.
In vivo study of SMT01 in nude mice. In vivo study was done
to evaluate SMT01 in two different aspects, dosage
dependent safety and toxicity and dosage efficacy at three
different concentrations of the NK cells (Tables I and II).
Intravenous infusion of SMT01 was administrated by
injecting the cells through tail venous of nude mice. Low
dose of SMT01 was 4×104 cell/animal which corresponds to
2×106 cells/kg in human. 2×105 cells/animal and 1×106
cells/animal were the intermediate and high doses of the
infusion, respectively. For the dosage dependent safety and
toxicity study, a total of 18 SMT01 infusions (2 injections
per 3 weeks) were performed at the three different dose
levels (Table I, Figure 1). The result showed that the mice
tolerated well the maximum dose of SMT01 and no death
caused from SMT01 infusion. All of the treatment groups did
not show toxicity response related to the NK cell
administration in the internal organs (data now shown). No
significant change of T and B lymphocytes was observed,
suggesting that SMT01 did not cause immune-related
adverse events (Table I).
In vivo cytolytic activity of SMT01 against CC was
evaluated. To do this, xenograftment of CC cells into nude
mice was performed. HuCCT-1 cells at 5×106 cells/ml were
subcutaneously transplanted on the back of 10 nude mice in
each group. After 8 days of CC cell transplantation, well
engrafted with similar tumor volumes nude mice, were
carefully selected and used for the in vivo study. For
treatment, eight selected mice from each treatment group
including negative (G1, normal saline infusion) control
group were intravenously administrated (Table II, Figure 1).
Chemo-administration as a positive control group (G5,
CDDP+Gem) was also done with the same number of mice.
After five administrations of the SMT01 divided into 3
different dose concentrations (G2-G4), the tumors were
dissected out from the nude mice and the tumor volume and
weight were measured (Figure 3). 
The mean tumor volumes observed at 55 days after
administration were 5324, 2769, 3491, 3193, and 2167 mm3
for G1, G2, G3, G4, and G5, respectively (Figure 3B). All of
the treatment groups except the negative control group (G1)
showed tumor growth inhibition. Extracted mean tumor
weights from the groups also revealed significant differences
between the treatment groups and the negative control group
(Figure 3A). The results indicated that SMT01 administration
showed a significant effect on tumor growth inhibition.
Although maximum growth inhibition was observed at the
chemo-administration group, no statistical significance was
obtained. More interestingly, however, when body weight
changes of all the treatment groups were evaluated, the
chemo-administrated group of mice showed significantly
lowered body weight (Figure 4A) and this was not related to
a food consumption problem (Figure 4B). All of the other
treatment groups of mice showed similar weight maintenance.
The results indicate that NK cell therapy has a beneficial
effect on weight maintenance which is relevant to the quality
of life, an important parameter in cancer therapeutic. 
Taken together, the in vivo study revealed that SMT01
apparently displayed cytolytic activity against cholangio-
carcinoma without significant side effects related to cell
infusions. 
Histologic evaluation of SMT01 activity in nude mice tumor.
SMT01’s cytolytic activity was evaluated by using tumor
tissue sections (Figures 5 and 6). Anti-human CD56 antibody
was efficiently used for IHC experiment to detect penetration
of NK cells into the HuCCT-1 tumor of nude mice
administrated with SMT01 infusion. The same tumor tissue
sections were used for TUNEL assay. 
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Table II. Summary of histopathological findings.
Group/                                   N                                       Apoptosis                                                                                   Necrosis
Dose 
                                                               Rate (%)                 ±                  +                ++                ±                 +                + +            + + +           + + ++
G1/0 cells/head                     8              8.17±1.26                8                   0                  0                  0                 5                  3                  0                   0
G2/4×104 cells/head             8             12.42±2.59               2                   6                  0                  0                 1                  5                  1                   1
G3/2×105 cells/head             8             11.71±3.73               3                   5                  0                  1                 3                  2                  2                   0
G4/1×106 cells/head             8             10.88±2.25               3                   5                  0                  0                 4                  3                  1                   0
G5/3+120 mg/kg                  8             23.00±3.35               0                   2                  6                  0                 4                  2                  2                   0
G1: Negative control (Normal saline); G2: SMT01, Low dose (4×104 cells/head); G3: SMT01, intermediate dose (2×105 cells/head); G4: SMT01,
High dose (1×106 cells/head); G5: Cis diammineplatinum (Ⅱ) dichloride (CDDP)+Gemcitabine (Gem); N: number of animals; Grade- ±: minimal,
+: mild, ++: moderate, +++: marked, ++++: severe.
IHC of tissue sections from G1 (normal saline infusion mice)
and G5 (Chemo-administrated mice) groups of mice showed
CD56 positive signal at background level. IHC of tissue
sections from the SMT01 infusion groups (G2-G4) clearly
showed CD56-positive cells mainly located at the cleavage
between the tumor nodules, suggesting that SMT01 penetrated
into the HuCCT-1 tumor developed in the nude mice (Figure
5). The IHC signals were found to be located where the tissue
in vivo 32: 771-781 (2018)
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Figure 3. Tumor growth inhibition of SMT01. A: Five different groups of nude mice and the tumors dissected out from the mice. G1, Normal saline;
G2-G4, SMT01 infusions. G5, Chemo-administration (GEM+CDDP, 120+3 mg/kg, respectively). G2, Low dose (4×104 cells/head); G3, Intermediate
dose (2×105 cells/head); G4, High dose (1×106 cells/head). B: Tumor volume. C: Tumor weight.
mass and density were loose inside the tumor due to feeding
vessel penetration (Figure 5, G2-G4, arrowhead). 
Infiltration of CD56-positive NK cells of the tumor tissue
was clearer at higher resolution of microscopy (Figure 6B).
As shown in Figure 6B, the CD56-positive NK cells were
densely detected at sites close to blood vessels in the mouse
groups (G2-G4) received SMT01 infusion. Similar result was
also obtained by IHC against a NK cell activating receptor,
NCR1, confirming that the penetrating cells were NK cells
(Figure 6B, see NCR1 panel figures). Apoptosis was also
detected by TUNEL staining and IHC against the apoptotic
marker caspase 3a (Figure 6A and B). The results revealed
that apoptotic tumor cells largely appeared in the tumor of
SMT01 infused and chemo-administration mice groups
(Figure 6A). Interestingly, apoptotic cells were more
frequently detected at the vicinity of the populated NK cells.
The result suggested that the extravasated NK cells exerted
their cytolytic activity primarily against tumor cells near the
tumor vessels. Taken together, the results revealed that
SMT01 displays cytotoxicity against cholangiocarcinoma. 
Discussion
Cytolytic activity of NK cells (SMT01) against CC cells.
Cholangiocarcinoma (CC) is a malignant tumor that
originates from the biliary duct epithelium. The carcinoma
is largely classified into two types: intrahepatic and
extrahepatic CC (19). Diagnosis and curative treatment for
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Figure 4. In vivo nude mice study of SMT01. A: Body weight change. B: Tumor volume change. Tumor volume was measured by using a caliper
(CD-15CX, Mitutoyo, Japan) and calculated as: TV (mm3)=L (mm) × W2 (mm2) × 1/2. G2 (Low dose) showed statistical significance p<0.01 at
days 23, 27, 30, 34, 44, 48, 51 and 55 during administration (p<0.05 at day 37, 41). G3 (Intermediate dose) p<0.05 at day 30, 37, 41, 51, and 55
(day 34, 44, and 48 p<0.01). G4 (High dose) p<0.01 at day 23, 30, 34, 37, 41, 44, 48, 51, and 55 (p<0.05 at day 20 and 27). G5 (CDDP+Gem)
p<0.01 at day 23-55). C: Tumor weight. Measured mean tumor weights: G1, 2.904 g (IR=0.0%); G2, 1.892 g (IR=34.8%); G3, 2.292 g (IR: 21.1%);
G4, 2.252 g (IR=22.4%); G5, 1.385 g (IR: 52.3%). IR (%)=(1-T/C)×100 (T: Mean tumor weight of the test substance group and positive substance
group C: Mean tumor weight of the negative control group).
CC are not easy because pathogenesis of the malignancy is
not fully understood while the disease is more likely
aggressive, infiltrating surrounding tissues and thus most of
the patients are inoperable at the time of diagnosis (20, 21).
Also, an alternative regimen for replacing the standard
chemotherapy is not available when the chemotherapy fails
to give a clinical response. Currently, Gem/CDDP regimen
is widely administered to patients at the inoperable stage.
The regimen however decreases quality of life (QOL) due
to toxicity. 
Our interest in developing an immune cell therapy for CC
is to provide an alternative treatment for the patients
diagnosed with an inoperable stage or who have had chemo-
failure as a 2nd line therapy. NK cells are one of the
lymphocytes with natural cytotoxicity to malignant cells. For
this reason, killing effect of the immune cells against various
types of cancer have been intensively studied in vitro using
the cancer cells (22) and also in vivo using animal models
(23). NK cells are now widely used as an innovative
immune-therapy. While autologous NK cell therapy has
in vivo 32: 771-781 (2018)
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Figure 5. H&E stain and IHC experiment of the nude mice tumor. Full morphology and CD56 IHC finding of the representative tumors from each
group is shown at a low magnification (12.5×). Magnified views (H&E and IHC images from consecutive sections) of rectangular boxes are shown
on the right columns (100×). CD56-positive NK cells in the group 2-4 (G2-G4) are mainly located along the cleavage between tumor nodules (red
arrowheads). 
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Figure 6. Histological observation of apoptotic tumor cells and infiltrating NK cells. A: TUNEL stains of all study group’s tumor sections. TUNEL-
positive cells were significantly more frequent in G2-G5 compared to G1. B: IHC experiments. a and b: Consecutive section images from G2 showing
NCR1-positive NK cell infiltration (red arrowheads) along the loose tissue between tumor nodules. c and d: Consecutive section images from G3
showing precisely matched CD56 and NCR1-positive NK cells. e-h: Consecutive section images from G3. Apoptotic signals of the tumor cells
detected by IHC with anti-human caspase 3a antibody are predominantly detected at the area with robust NK cell infiltration. i and j: Consecutive
section images from G4. In the tumor, caspase3a-positive cells (black arrowheads) are detected at the vicinity where infiltrated NK cells are detected
(red arrowheads). k and l: Consecutive section images from G4. Caspase3a-positive cells (black arrowheads) are located at the vicinity of NK cell
infiltration (red arrowheads) along loose tissue between tumor nodules. m-p: Consecutive section images from G1 and G5 showing spotty caspase3a-
positive cells (black arrowheads) in the tumor irrelevant to NK cell infiltration.
previously shown limited clinical response, many of the
molecular and clinical studies have now focus on the use of
NK cells prepared from healthy blood donors overcoming
the clinical weaknesses of using autologous NK cells.
Unfortunately, however, no NK cell therapy for CC has been
available. Thus, the primary goal of this in vivo study by
using a nude mouse model was to determine whether NK
cell therapy is clinically potent CC. 
In this study, ex vivo expanded NK cells (SMT01) were
used to investigate the cytolytic activity of cells against CC.
As demonstrated in Figure 2A, SMT01 are highly purified NK
cells with T cells depletion. These NK cells were used in in
vitro and in vivo studies to examine their cytotoxicity activity
against CC cells. In-vitro study of SMT01 was efficiently
performed by the CCK-8 assay in which the number of target
cells survived following administration of NK cells was
measured and the results showed that SMT01 displayed an
enhanced cytolytic activity to HuCCT-1 and SNU308 cells and
somewhat lower activity to SNU1196 and SNU479 cells
(Figure 2B). Further in vivo analysis of the cytolytic activity
of SMT01 was performed by choosing HuCCT-1 cells.
In vivo study of SMT01 and pre-clinical relevance of NK cell
therapy against CC. In vivo cytolytic activity of SMT01 was
investigated by generating a xenografted CC tumor in nude
mice. To do this, we selected and transplanted HuCCT-1 cells
into nude mice. The xenografted nude mice, grouped into 3
different dosage groups, received multiple infusions of SMT01
(Figure 1 and Table II). Normal saline infusion was used as a
negative control group (G1) and chemo-administration with
CDDP+Gem (G5) was used as a positive control. The cytolytic
activity in these groups was compared to that of the SMT01
infusion groups (G2-G4). When a total of five treatments was
given to the different nude mice groups, SMT01 infusions were
found to inhibit CC tumor growth (Figure 3A). Measurement
of tumor volume and weight done by dissecting out the CC
tumors from the xenografted nude mice revealed that the
negative control group (G1) administrated with normal saline
contained the largest tumor volume and also the heaviest
weight, as expected, while all of the other treatment groups
showed a significantly reduced tumor volume and weight,
suggesting that both NK cell therapy and chemo-therapy
effectively worked to kill CC cells (Figure 3B). When the body
weight of the nude mice was measured, however, that of the
chemo-administrated group (G5) was found to be maintained
at the lowest level among the five groups (Figure 4A) and this
was not related to food consumption (Figure 4B). This suggests
that chemo-administration is more stressful and is not
beneficial in relevance to QOL, although the treatment showed
the highest inhibitory effect on CC tumor growth.
As the dosage dependent safety and toxicity concerns that
may be caused from SMT01 infusions, a total of 18 repeated
SMT01 infusions were performed by intravenous tail injection
to the nude mice with 10-day intervals for a total of 27 weeks
(Figure 1A). The nude mice well tolerated all three doses, low
(G2), intermediate (G3), and high (G4) (Table I). No death or
SAE related to NK cell infusion was observed. The result
suggested that SMT01 administration is at least pre-clinically
safe. Unexpectedly, dose-dependent tumoricidal effect of NK
cells, was not observed.
Histological evidence of SMT01 invasion into CC tumor.
Histology, IHC, and TUNEL experiments were performed to
demonstrate SMT01 activity inside the HuCCT-1 tumor
(Figures 5 and 6). To do this, the tumors dissected out from the
nude mice were used to prepare the consecutive tissue section
for those experiments. Despite the fact that histologic evaluation
was performed 14 days after the last infusion of SMT01 (Figure
1B), CD56-positive NK cells infiltrated into the tumors of all
SMT01 infusion groups were observed (Figures 5 and 6).
Considering lifespan of NK cells to be approximately 2 weeks
(24), it was quite interesting to observe a robust NK cell
infiltration into the tumors (Figures 5 and 6B, red arrowheads).
This may indicate the xenogenic nature of SMT01 treatment
with a prolonged cytolytic activity against CC cells in mice. 
TUNEL staining (Figure 6A) and IHC experiment for
caspase 3a (Figure 6B) also suggested that apoptosis was
underway inside the tumor. Unlikely the immune cell therapy
application for hematologic malignancies, solid cancers
generally do not show penetration of the immune cells deep
into the tumor mass. We also found infiltrating CD56-
positive NK cells densely and primarily located along the
tumor vessels, and the apoptotic tumor cells were found at
the vicinity of the populated NK cells. These findings
suggest that the dying tumor cells were caused truly by the
extravasated NK cell’s. In deep sites of tumor mass,
however, NK cells were seldomly observed, indicating that
immune cell penetration remains an unsolved issue. The
histopathological findings of the tumors from the five
different groups are summarized in Table II.
In summary, this in vitro and in vivo study with NK cells
demonstrated their cytotoxic effect to CC cells. The pre-
clinical study results obtained from nude mice bearing CC
tumors may not be the same or similar when the NK cell
therapy is clinically applied to CC patients. Thus, further
clinical study with SMT01 against CC is necessary to
investigate clinical responses.  
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